Journal of Clinical Oncology
Articles in this Issue
Electronic health records (EHR)-based machine learning (ML) approach to predict risk of progression to metastatic melanoma after initial diagnosis.
9560 Background: Strategies to predict progression to metastasis in early-stage melanoma patients have relied on a limited sample size and a limited set o...
Chemotherapy progression decision score to improve subsequent treatment regimen selection after initial assessment for pancreatic ductal adenocarcinoma.
e16388 Background: This study aims to develop a chemotherapy progression decision (cPD) score for pancreatic ductal adenocarcinoma (PDAC), designed as a c...
Phase II trial of neoadjuvant chemotherapy (NAC) docetaxel-cisplatin alone (DC) or with anti-human papillomavirus (HPV) gene therapy PRGN-2009 (DCP) followed by surgery in patients (pts) with newly diagnosed HPV-associated oropharyngeal cancer (HPV-OPC).
TPS6117 Background: HPV-OPC is caused primarily by HPV16. Prognosis following standard-of-care (SOC) treatment, (surgery followed by adjuvant radiotherapy...
The accuracy of cell-free DNA blood-based tests in the detection of gastric cancer: An exploratory meta-analysis.
e16158 Background: Gastric Cancer (GC) is the 5th most common type of cancer worldwide, accounting for around one million new cases per year. Although ear...
Risk factors for early-onset colorectal cancer: A retrospective analysis of 3,369 cases.
e15671 Background: Early-onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosed in individuals under the age of 50, has been increa...
Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery for long term outcome and analysis: CTRT:2022/01/050234.
e16327 Background: A prospective study evaluating the role of stereotactic body radiotherapy (SBRT) with cyber knife (CK) in hepatocellular carcinoma (HCC...
Racial disparities in major adverse cardiovascular and cerebrovascular events outcomes among hospitalized cholangiocarcinoma patients.
e23097 Background: Cholangiocarcinoma presents significant treatment challenges, with racial and ethnic disparities influencing clinical outcomes. This st...
Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.
e15558 Background: The BRAF inhibitor (BRAFi) encorafenib is currently approved in combination with the anti-EGFR agent cetuximab for patients with previo...
Prevalence and outcomes of lung abscess in hospitalized lung cancer patients: Insights from the Nationwide Inpatient Sample.
e20067 Background: Lung abscess is a common complication of pneumonia, frequently associated with significant morbidity. In lung cancer patients, abscess...
A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and/or locally advanced or metastatic hepatocellular carcinoma.
TPS4217 Background: IL-27 is a heterodimerized cytokine, a member of the IL-12/IL-23 cytokine family, and an immunoregulatory cytokine expressed by myeloi...
Trends in mortality from endocrine neoplasms in the United States: A CDC WONDER analysis (1999–2020).
e23218 Background: Endocrine neoplasms (EN) are invasive tumors of ductless glands with significant mortality risks. Over the past two decades, mortality...
Molecular-genetic characteristics of soft tissue sarcomas associated with the development of chemotherapy resistance.
11550 Background: The development of resistance is the one of the reason for ineffective treatment of soft tissue sarcomas (STSs). The search for new mole...
Individual and contextual factors associated with incidence of ovarian cancer in the United States.
e17545 Background: Ovarian cancer has the worst prognosis and highest death rate of all gynecological cancers in the US. Since data on incidence and risk...
Long-term efficacy and safety of disitamab vedotin monotherapy versus chemotherapy in bladder-preserving treatment of Chinese real-world patients with muscle-invasive urothelial cancer: A retrospective real-world study.
e16578 Background: The validity and effectiveness of Trimodality Therapy (TMT) which employing optimizing transurethral resection of bladder tumors (TURBT...
A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).
TPS5117 Background: Prostate-specific membrane antigen (PSMA) targeted radioligand therapy is an emerging treatment modality for metastatic castration-res...
JAVEMACS chart review study of avelumab maintenance in patients with advanced urothelial carcinoma (aUC) in Japan: Analyses of subgroups defined by second-line (2L) treatment.
e16550 Background: Avelumab maintenance is approved in Japan for patients with curatively unresectable UC not progressed after platinum-based chemotherapy...
Trends in Brazilian oncology studies over the last 5 ASCO Annual Meetings and their representation of Brazilian Oncology Census data.
e23108 Background: The ASCO Annual Meeting attracts global interest. Based on the 2023 Brazilian Oncology Census (BOC), Brazil has an estimated 4,730 prac...
Epidemiologic factors and survival outcomes of patients with metastatic malignant melanoma.
e21510 Background: Malignant melanoma has become one of the most common malignancies, with high survival rates if treated early. Recent studies have shown...
Toxicity profile of fruquintinib (Fruq) versus regorafenib (Rego) in refractory metastatic colorectal cancer (mCRC).
e15608 Background: Anti-VEGF TKIs are a cornerstone in the management of refractory mCRC. Fruq is FDA-approved for refractory mCRC that has similar effica...
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).
8501 Background: TROPION-Lung02 (NCT04526691) evaluated the TROP2-directed antibody-drug conjugate (ADC) Dato-DXd plus pembro combination with or without...
Mapping biological networks in lung adenocarcinoma using transcriptomic analysis to identify prognostic biomarkers and therapeutic targets.
e20038 Background: Lung adenocarcinoma (LUAD) is among the most frequently diagnosed cancers worldwide and remains a leading cause of cancer-related morta...
Investigating gender-based differences in the molecular profile of myeloid neoplasms: Insights from an institutional genomic database.
e18598 Background: Myeloid neoplasms exhibit significant gender-based differences in mutations and outcomes. Men have been shown to harbor more somatic mu...
Combined anti-angiogenic chemoradiotherapy with PD-1 monoclonal antibody for Chinese patients with advanced melanoma: A prospective single-arm study.
e21522 Background: Malignant melanoma, characterized by its aggressiveness and early metastasis, poses significant challenges in terms of treatment effica...
Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC).
6045 Background: Spatial transcriptomics (ST) revealed conserved malignant leading edge (LE) and tumor core (TC) architectures in primary oral squamous ce...
Preliminary results of 3D telomeres profiling for myeloma MRD and evaluation of concordance between blood and marrow.
e19560 Background: Recent meta-analyses have demonstrated the importance of minimal residual disease (MRD) as a prognostic factor in multiple myeloma (MM)...